Article: Nicotinamide Riboside and Calorie Restriction Improve Gut Microbiota and Reduce Liver Fat and Inflammation: Preclinical Findings

PrevNext
Digestive/Gut Health Liver Health Obesity Preclinical

Nicotinamide Riboside and Calorie Restriction Improve Gut Microbiota and Reduce Liver Fat and Inflammation: Preclinical Findings

Synopsis

Metabolic dysfunction–related fatty liver disease currently has no specific therapy. This study tested nicotinamide riboside (NR) and dietary restriction (DR) in rats with diet-induced obesity. High-fat cafeteria diets caused liver fat buildup, inflammation, and fibrosis, while DR delayed most liver problems. NR specifically reduced liver fat, cholesterol, and collagen buildup and limited harmful gut bacteria. Combining NR with DR also decreased liver size and inflammation. These findings suggest that NR may help protect the liver and support dietary strategies in fatty liver disease.

Journal

Nutrition

Share

Read more

Digestive/Gut Health

Nicotinamide Riboside Alters Gut Microbiota to Reduce Weight Gain from High-Fat Diet in Mice: Preclinical Findings

SynopsisThe gut microbiome influences energy balance and obesity risk. Nicotinamide riboside (NR), a vitamin B3 form and NAD+ precursor, can reduce weight gain and increase energy use in obese mice...

Read more
Metabolic Health

NAD+ Supports Metabolism in Impaired Urea Cycle: Preclinical Findings

SynopsisProblems in the urea cycle and how they relate to obesity and inflammation are not well understood, partly because classical urea cycle defects are severe and dramatic. To study this, resea...

Read more